Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma

Neal  Bhatia; Jonathan  Kantor; Lawrence  Green; Jonathan  Weiss; Cynthia Willson; Susan Cutler; Jayson Rieger; David K. Glover; Pamela Rumney; Gary Goldenberg

doi:10.25251/skin.7.supp.260

Neal Bhatia, MD

Therapeutics Clinical Research, San Diego, CA

Jonathon Kantor, MD

Florida Center for Dermatology, St. Augustine, FL

Lawrence Green, MD

Dept. of Dermatology, George Washington University School of Medicine, Washington DC

Jonathon Weiss, MD

Georgia Dermatology Partners and Gwinnett Clinical Research Center Inc., Snellville, GA

Cynthia Wilson, RN, BSN

Verrica Pharmaceuticals Inc., West Chester, PA

Susan Cutler, DMD

Verrica Pharmaceuticals Inc., West Chester, PA

Jayson Rieger, PhD, MBA

PBM Capital Group, Charlottesville, VA

David K. Glover, ME, PhD

PBM Capital Group, Charlottesville, VA

Pamela Rumney, RN, CCRC

Verrica Pharmaceuticals Inc., West Chester, PA

Gary Goldenberg, MD

Verrica Pharmaceuticals Inc., West Chester, PA, Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, NY, NY.

Keywords

Basal Cell Carcinoma

Abstract

References

1. Sveinbjørnsson, Baldur et al. “LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment.” Future Medicinal Chemistry 9 12 (2017): 1339-1344.

2. Eike LM, Yang N, Rekdal Ø, Sveinbjørnsson B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget. 2015 Oct 27;6(33):34910-23.

PDF

Published

Nov 13, 2023

DOI https://doi.org/10.25251/skin.7.supp.260

How to Cite

[1]

Bhatia, N. , Kantor, J. , Green, L. , Weiss, J. , Willson, C., Cutler, S., Rieger, J., Glover, D.K., Rumney, P. and Goldenberg, G. 2023. Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s260. DOI:https://doi.org/10.25251/skin.7.supp.260.

Issue

Vol. 7 No. 6 (2023): November 2023 Issue

Section

Skin Cancer

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Linda Stein Gold, Mark Lebwohl, Neal Bhatia, Douglas DiRuggiero, Abby Jacobson, Radhakrishnan Pillai, Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, Andrew Blauvelt, April Armstrong , Seemal Desai, Howard Sofen, Lawrence Green, Steve Tyring, Laura Ferris, Philip Brown, David Rubenstein, Stephen Piscitelli, Anna Tallman, Leon Kircik, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Secondary Efficacy Outcomes from Two Pivotal Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Danny Zakria, Milaan Shah, Joshua Burshtein, Brian Berman, Neal Bhatia, Roger Ceilley, Aaron Farberg, Mark Lebwohl, Dawn Merritt, Keyvan Nouri, Linda Stein Gold, Darrell Rigel, The Role of Field Cancerization in Selecting Therapies for Actinic Keratosis: An Expert Consensus Panel , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 3 (2024): May 2024 Issue
Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Albert Torra, David Cutler, Mark Lebwohl, Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Matthew Zirwas, Zoe Draelos, Janet Dubois, Leon Kircik, Angela Moore, Linda Stein Gold, Javier Alonso-Llamazares, Michael Bukhalo, Suzanne Bruce, Kimmie Eads, Lawrence Green, Scott Guenthner, Laura Ferris, Seth Forman, Steven Kempers, Edward Lain, Charles Lynde, David Pariser, David Pariser, Darryl Toth, paul Yamauchi, Patrick Burnett, David Berk, A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
James Del Rosso, Jeffrey Sugarman , Michael Gold, Krysten Arekapdui, Lawrence Green, A New Frontier in Acne Treatment: Encapsulated Benzoyl Peroxide and Tretinoin , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Linda Stein Gold, MD, Leon H. Kircik, MD, William Philip Werschler, MD, Hilary Baldwin, MD, Valerie Callender, MD, Lawrence Green, MD, Neil Sadick, MD, Jeffrey L. Sugarman, MD, PhD, Zoe D Draelos, MD, Emil A Tanghetti, MD, Neal Bhatia, MD, Impact of Age or Sex on Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%/Benzoyl Peroxide 3.1%/Adapalene 0.15% Gel in Participants with Moderate-to-Severe Acne , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
Jerry Bagel, Linda Stein Gold, James Del Rosso, Neal Bhatia, Sandy Johnson , Paul Yamauchi, Angela Moore, Anna Tallman, Patient Satisfaction with Tapinarof Cream 1% Once Daily for Plaque Psoriasis in a Long-Term Extension Trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
James Del Rosso, Leon Kircik, Linda Stein Gold, Hilary Baldwin, Jonathan Weiss, David Pariser, Valerie Callender, Edward Lain, Michael Gold, Kenneth Beer, Zoe Draelos, Neil Sadick, ; Radhakrishnan Pillai, Varsha Bhatt, Emil Tanghetti, Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: Phase 2 Study of the First Triple-Combination Drug , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
James Del Rosso, Neal Bhatia, Hilary Baldwin, Linda Stein Gold, Seemal Desai, Sam Brantman, Critical Evaluation of Benzoyl Peroxide in Rosacea: Old Challenges and New Clinical Opportunities With Encapsulated Benzoyl Peroxide , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)

<< < 1 2 3 4 5 6 7 8 9 10 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)